Novartis India has informed about Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended June 30, 2017.
The above information is a part of company’s filings submitted to BSE.